Literature DB >> 25477072

Translational control by oncogenic signaling pathways.

Beichen Gao1, Philippe P Roux2.   

Abstract

Messenger RNA (mRNA) translation is highly regulated in cells and plays an integral role in the overall process of gene expression. The initiation phase of translation is considered to be the most rate-limiting and is often targeted by oncogenic signaling pathways to promote global protein synthesis and the selective translation of tumor-promoting mRNAs. Translational control is a crucial component of cancer development as it allows cancer cells to adapt to the altered metabolism that is generally associated with the tumor state. The phosphoinositide 3-kinase (PI3K)/Akt and Ras/mitogen-activated protein kinase (MAPK) pathways are strongly implicated in cancer etiology, and they exert their biological effects by modulating both global and specific mRNA translation. In addition to having respective translational targets, these pathways also impinge on the mechanistic/mammalian target of rapamycin (mTOR), which acts as a critical signaling node linking nutrient sensing to the coordinated regulation of cellular metabolism. mTOR is best known as a central regulator of protein synthesis and has been implicated in an increasing number of pathological conditions, including cancer. In this article, we describe the current knowledge on the roles and regulation of mRNA translation by various oncogenic signaling pathways, as well as the relevance of these molecular mechanisms to human malignancies. This article is part of a Special Issue entitled: Translation and cancer.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; MAPK; Protein synthesis; mRNA translation; mTOR; mTORC1

Mesh:

Substances:

Year:  2014        PMID: 25477072     DOI: 10.1016/j.bbagrm.2014.11.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  23 in total

1.  Estrogen receptor α promotes protein synthesis by fine-tuning the expression of the eukaryotic translation initiation factor 3 subunit f (eIF3f).

Authors:  Rafael Cuesta; Adi Y Berman; Anya Alayev; Marina K Holz
Journal:  J Biol Chem       Date:  2018-12-20       Impact factor: 5.157

2.  IGF2 mRNA binding protein 3 (IMP3) mediated regulation of transcriptome and translatome in glioma cells.

Authors:  Shruti Bhargava; Vikas Patil; Riyaz Ahmad Shah; Kumaravel Somasundaram
Journal:  Cancer Biol Ther       Date:  2017-12-19       Impact factor: 4.742

Review 3.  Targeting AMPK for the Alleviation of Pathological Pain.

Authors:  Marina N Asiedu; Gregory Dussor; Theodore J Price
Journal:  Exp Suppl       Date:  2016

Review 4.  Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases.

Authors:  Scott T Brady; Gerardo A Morfini
Journal:  Neurobiol Dis       Date:  2017-04-11       Impact factor: 5.996

Review 5.  Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?

Authors:  Yong Weon Yi; Kyu Sic You; Jeong-Soo Park; Seok-Geun Lee; Yeon-Sun Seong
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

6.  Mitogenic signaling pathways in the liver of growth hormone (GH)-overexpressing mice during the growth period.

Authors:  Carolina S Martinez; Verónica G Piazza; Lorena González; Yimin Fang; Andrzej Bartke; Daniel Turyn; Johanna G Miquet; Ana I Sotelo
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 7.  Maf1, A New PTEN Target Linking RNA and Lipid Metabolism.

Authors:  Deborah L Johnson; Bangyan L Stiles
Journal:  Trends Endocrinol Metab       Date:  2016-06-10       Impact factor: 12.015

8.  A Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells.

Authors:  Timothy D Martin; Danielle R Cook; Mei Yuk Choi; Mamie Z Li; Kevin M Haigis; Stephen J Elledge
Journal:  Cell Rep       Date:  2017-07-11       Impact factor: 9.423

Review 9.  RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

Authors:  Julian Downward
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

10.  4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer.

Authors:  Blake A Jacobson; Zeeshan Ahmad; Sierra Chen; Gabriella Waldusky; Maxwell Dillenburg; Emilia Stoian; Daniel A Cambron; Anil J Patel; Manish R Patel; Carston R Wagner; Robert A Kratzke
Journal:  Invest New Drugs       Date:  2020-11-23       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.